drugset / Trial / NCT05614648

Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet

NCT05614648

Phase 3 Terminated 17 enrolled Sollis Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and effectiveness of a new pain medication in development, clonidine micropellet. Participants will receive a single injection of either clonidine micropellet or sham injection for the treatment of low back and leg pain from sciatica.

Timeline

Start
2023-06-19
Primary completion
2024-03-18
Completion
2024-03-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clonidine Other / unclassified 0.975 mg Other

Indications